-
3
-
-
0022546602
-
Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells
-
CHEEVER, M.A., THOMPSON, D.B., KLARNET, J.P. and GREENBERG, P.D., Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J. exp. Med., 163, 1100-1112 (1986).
-
(1986)
J. Exp. Med.
, vol.163
, pp. 1100-1112
-
-
Cheever, M.A.1
Thompson, D.B.2
Klarnet, J.P.3
Greenberg, P.D.4
-
4
-
-
0027996540
-
Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte macrophage colony-stimulating factor
-
CHEN, T.T., TAO, M.H. and LEVY, R., Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte macrophage colony-stimulating factor. J. Immunol., 153, 4775-4787 (1994).
-
(1994)
J. Immunol.
, vol.153
, pp. 4775-4787
-
-
Chen, T.T.1
Tao, M.H.2
Levy, R.3
-
5
-
-
0003747871
-
-
Wiley, New York
-
COLIGAN, J.E., KRUISBEEK, A.M., MARGULIES, D.H., SHEVACH, E.M. and STROBER, W., Current protocols in immunology, Wiley, New York (1995).
-
(1995)
Current Protocols in Immunology
-
-
Coligan, J.E.1
Kruisbeek, A.M.2
Margulies, D.H.3
Shevach, E.M.4
Strober, W.5
-
6
-
-
0029919272
-
Immunotherapy of cancer with genetically modified tumor vaccines
-
GILBOA, E., Immunotherapy of cancer with genetically modified tumor vaccines. Semin. Oncol., 23, 101-107 (1996).
-
(1996)
Semin. Oncol.
, vol.23
, pp. 101-107
-
-
Gilboa, E.1
-
7
-
-
0027598183
-
Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins
-
GILLIES, S.D., YOUNG, D., Lo, K.M. and ROBERTS, S., Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconj. Chem., 4, 230-235 (1993).
-
(1993)
Bioconj. Chem.
, vol.4
, pp. 230-235
-
-
Gillies, S.D.1
Young, D.2
Lo, K.M.3
Roberts, S.4
-
8
-
-
0021686808
-
Treatment of disseminated leukemia with cyclophosphamide and immune cells: Tumor immunity reflects long-term persistence of tumor specific donor cells
-
GREENBERG, P.D. and CHEEVER, M.A., Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor specific donor cells. J. Immunol., 133, 3401-3407 (1984).
-
(1984)
J. Immunol.
, vol.133
, pp. 3401-3407
-
-
Greenberg, P.D.1
Cheever, M.A.2
-
9
-
-
0031439719
-
Human tumor antigens recognized by T-cells
-
KAWAKAMI, Y. and ROSENBERG, S.A., Human tumor antigens recognized by T-cells. Immunol. Res., 16, 313-339 (1997).
-
(1997)
Immunol. Res.
, vol.16
, pp. 313-339
-
-
Kawakami, Y.1
Rosenberg, S.A.2
-
10
-
-
0342636415
-
Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma
-
KIM, T.S. and COHEN, E.P., Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res., 54, 2531-2535 (1994).
-
(1994)
Cancer Res.
, vol.54
, pp. 2531-2535
-
-
Kim, T.S.1
Cohen, E.P.2
-
11
-
-
0031134912
-
An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production
-
KIM, T.S., DEKRUYFF, R.H., RUPPER, R., MAECKER, H.T., LEVY, S. and UMETSU, D.T., An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J. Immunol., 158, 4137-4144 (1997).
-
(1997)
J. Immunol.
, vol.158
, pp. 4137-4144
-
-
Kim, T.S.1
Dekruyff, R.H.2
Rupper, R.3
Maecker, H.T.4
Levy, S.5
Umetsu, D.T.6
-
12
-
-
0027437513
-
Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma
-
KIM, T.S., RUSSELL, S.J., COLLINS, M.K.L. and COHEN, E.P., Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma. Int. J. Cancer, 55, 865-872 (1993).
-
(1993)
Int. J. Cancer
, vol.55
, pp. 865-872
-
-
Kim, T.S.1
Russell, S.J.2
Collins, M.K.L.3
Cohen, E.P.4
-
13
-
-
0028981435
-
Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma
-
KIM, T.S., XU, W.S., SUN, T. and COHEN, E.P., Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma. Melanoma Res., 5, 217-227 (1995).
-
(1995)
Melanoma Res.
, vol.5
, pp. 217-227
-
-
Kim, T.S.1
Xu, W.S.2
Sun, T.3
Cohen, E.P.4
-
14
-
-
0026015202
-
The immunotherapy of human cancer with interleukin 2: Present status and future directions
-
KOLITZ, J.E. and MERTELSMANN, R., The immunotherapy of human cancer with interleukin 2: present status and future directions. Cancer Invest., 9, 529-542 (1991).
-
(1991)
Cancer Invest.
, vol.9
, pp. 529-542
-
-
Kolitz, J.E.1
Mertelsmann, R.2
-
15
-
-
0031805796
-
Potentiation of antigen-specific, Th1 immune responses by multiple DNA vaccination with an ovalbumin/interferon-gamma hybrid construct
-
LIM, Y.S., KANG, B.Y., KIM, E.J., KIM, S.H., HWANG, S.Y. and KIM, T.S., Potentiation of antigen-specific, Th1 immune responses by multiple DNA vaccination with an ovalbumin/interferon-gamma hybrid construct. Immunology, 94, 135-141 (1998).
-
(1998)
Immunology
, vol.94
, pp. 135-141
-
-
Lim, Y.S.1
Kang, B.Y.2
Kim, E.J.3
Kim, S.H.4
Hwang, S.Y.5
Kim, T.S.6
-
16
-
-
0032525876
-
Targeting p53 for adoptive T-cell immunotherapy
-
MCCARTY, T.M., LIU, X., SUN, J.Y., PERALTA, E.A., DIAMOND, D.J. and ELLENHORN, J.D., Targeting p53 for adoptive T-cell immunotherapy. Cancer Res., 58, 2601-2605 (1998).
-
(1998)
Cancer Res.
, vol.58
, pp. 2601-2605
-
-
McCarty, T.M.1
Liu, X.2
Sun, J.Y.3
Peralta, E.A.4
Diamond, D.J.5
Ellenhorn, J.D.6
-
17
-
-
0020047427
-
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor dependent on elimination of tumor-induced suppressor cells
-
NORTH, R.J., Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor dependent on elimination of tumor-induced suppressor cells. J. exp. Med., 155, 1063-1074 (1982).
-
(1982)
J. Exp. Med.
, vol.155
, pp. 1063-1074
-
-
North, R.J.1
-
18
-
-
0024490846
-
Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia
-
PEACE, D.J. and CHEEVER, M.A., Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia. J. exp. Med., 161, 161-173 (1989).
-
(1989)
J. Exp. Med.
, vol.161
, pp. 161-173
-
-
Peace, D.J.1
Cheever, M.A.2
-
19
-
-
0031832638
-
Systemic T cell adoptive immunotherapy of malignant gliomas
-
PLAUTZ, G.E., BARNETT, G.H., MILLER, D.W., COHEN, B.H., PRAYSON, R.A., KRAUSS, J.C., LUCIANO, M., KANGISSER, D.B. and SHU, S., Systemic T cell adoptive immunotherapy of malignant gliomas. J. Neurosurg., 89, 42-51 (1998).
-
(1998)
J. Neurosurg.
, vol.89
, pp. 42-51
-
-
Plautz, G.E.1
Barnett, G.H.2
Miller, D.W.3
Cohen, B.H.4
Prayson, R.A.5
Krauss, J.C.6
Luciano, M.7
Kangisser, D.B.8
Shu, S.9
-
20
-
-
0031424935
-
Keynote address: Perspectives on the use of interleukin-2 in cancer treatment
-
ROSENBERG, S.A., Keynote address: perspectives on the use of interleukin-2 in cancer treatment. Cancer J. sci. Amer., 3, S2-S6 (1997).
-
(1997)
Cancer J. Sci. Amer.
, vol.3
-
-
Rosenberg, S.A.1
-
21
-
-
0030779785
-
UV-induced N-ras mutations are T-cell targets in human melanoma
-
VAN ELSAS, A., SCHEIBENBOGEN, C., VAN DER MINNE, C., ZERP, S.F., KEILHOLZ, U. and SCHRIER, P.I., UV-induced N-ras mutations are T-cell targets in human melanoma. Melanoma Res., Suppl., 2, S107-S113 (1997).
-
(1997)
Melanoma Res., Suppl.
, vol.2
-
-
Van Elsas, A.1
Scheibenbogen, C.2
Van Der Minne, C.3
Zerp, S.F.4
Keilholz, U.5
Schrier, P.I.6
-
22
-
-
0024264288
-
Acute immunologic effects of interleukin-2 therapy in cancer patients: Decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens
-
WIEBKE, E.A., ROSENBERG, S.A. and LOTZE, M.T., Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. J. clin. Oncol., 6, 1440-1449 (1988).
-
(1988)
J. Clin. Oncol.
, vol.6
, pp. 1440-1449
-
-
Wiebke, E.A.1
Rosenberg, S.A.2
Lotze, M.T.3
-
23
-
-
0032170538
-
Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases
-
XIANG, R., LODE, H.N., DREIER, T., GILLIES, S.D. and REISFELD, R.A., Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases. Cancer Res., 58, 3918-3925 (1998).
-
(1998)
Cancer Res.
, vol.58
, pp. 3918-3925
-
-
Xiang, R.1
Lode, H.N.2
Dreier, T.3
Gillies, S.D.4
Reisfeld, R.A.5
-
24
-
-
0030656557
-
Prospects for adoptive T cell therapy
-
YEE, C., RIDDELL, S.R. and GREENBERG, P.D., Prospects for adoptive T cell therapy. Curr. Opin. Immunol., 9, 702-708 (1997).
-
(1997)
Curr. Opin. Immunol.
, vol.9
, pp. 702-708
-
-
Yee, C.1
Riddell, S.R.2
Greenberg, P.D.3
|